电邮这篇文章 Synthesis of (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside
- 作者: Khalikova M.J.1, Roziqov U.A.1, Skrylkova A.S.2, Egorov D.M.2, Safarov S.S.1
-
隶属关系:
- V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
- St. Petersburg State Institute of Technology (Technical University)
- 期: 卷 60, 编号 4 (2024)
- 页面: 516-522
- 栏目: Articles
- URL: https://ter-arkhiv.ru/0514-7492/article/view/672180
- DOI: https://doi.org/10.31857/S0514749224040137
- EDN: https://elibrary.ru/RYNANK
- ID: 672180
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
The article presents a method for the preparation of (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside from (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-1,2-O-isopropylidene-α-L-talofuranoside by successive treatment of the latter with a 20% solution of hydrochloric acid in aqueous methanol, followed by treatment with benzoyl chloride in dry pyridine. A promising use of methyl (1S,2S,3R,4R,5S)-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside for the synthesis of new modified nucleosides after its acetylation has also been shown.
作者简介
M. Khalikova
V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
Email: diavoly@mail.ru
塔吉克斯坦, ul. Ayni, 299/2, Dushanbe, 734063
U. Roziqov
V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
Email: diavoly@mail.ru
塔吉克斯坦, ul. Ayni, 299/2, Dushanbe, 734063
A. Skrylkova
St. Petersburg State Institute of Technology (Technical University)
Email: diavoly@mail.ru
俄罗斯联邦, Moskovskii prosp., 26, St. Petersburg, 190013
D. Egorov
St. Petersburg State Institute of Technology (Technical University)
编辑信件的主要联系方式.
Email: diavoly@mail.ru
ORCID iD: 0000-0003-3744-9306
俄罗斯联邦, Moskovskii prosp., 26, St. Petersburg, 190013
S. Safarov
V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
Email: diavoly@mail.ru
ORCID iD: 0000-0002-7193-6135
塔吉克斯坦, ul. Ayni, 299/2, Dushanbe, 734063
参考
- Fischer E., Piloty O. Ber. Dtsch. Chem. Ges. 1891, 24, 4214–4225. doi: 10.1002/cber.189102402322
- Eugenio F., Lourdes R. J. Biol. Chem. 2019, 294, 2249–2255. doi: 10.1074/jbc.CL119.007397.
- Jeanloz R.W., Fletcher H. G. Adv. Carbohydr. Chem. 1951, 6, 135–174. doi: 10.1016/S0096–5332(08)60066–1.
- Mao-Chin L., Mei-Zhen L., Diane E. M., Alan C. S. Nucleosid. Nucleotid. Nucleic. Acids. 2005, 24, 45–62. doi: 10.1081/NCN-46784.
- Hassan A.E.A., Abou-Elkhair R.A.I., Parker W. B., Allan P. W., Secrist III J. A. Bioorg. Chem. 2016, 65, 9–16. doi: 10.1016/j.bioorg.2015.12.006.
- Chhikara B.S., Parang K. Expert Opin. Drug Deliv. 2010, 7, 1399–1414. doi: 10.1517/17425247.2010.527330.
- Li Y., Li P., Li Y., Zhang R., Yu P., Ma Z., Kainov D. E., de Man R. A., Peppelenbosch M. P., Pan Q. Antivir. Res. 2020, 184, 104967. doi: 10.1016/j.antiviral.2020.104967.
- Cihák A. Oncology. 1974, 30, 405–422. doi 10.1159/ 000224981.
- Liliemark J. Clin. Pharmacokinet. 1997, 32, 120–131. doi: 10.2165/00003088–199732020–00003.
- Kantarjian H.M., O′Brien S., Cortes J., Giles F. J., Faderl S., Issa J. P., Garcia-Manero G., Rios M. B., Shan J., Andreeff M., Keating M., Talpaz M. Cancer. 2003, 98, 522–528. doi: 10.1002/cncr.11543.
- Allen-Mersh T.G., Earlam S., Fordy C., Abrams K., Houghton J. Lancet. 1994, 344, 1255–1260. doi: 10.1016/S0140–6736(94)90750–1.
- Tournilhac O., Cazin B., Leprètre S., Diviné M., Maloum K., Delmer A., Grosbois B., Feugier P., Maloisel F., Villard F., Villemagne B., Bastit D., Belhadj K., Azar N., Michallet M., Manhès G., Travade P. Blood. 2004, 103, 363–365. doi: 10.1182/blood-2003–05–1449.
- http://www.cancer.gov/cancertopics/druginfo/fda-nelarabine; Архивная копия от 11 сентября 2014 на Wayback Machine FDA Approval for Nelarabine.
- Wangsomboonsiri W., Mahasirimongkol S., Chantarangsu S., Kiertiburanakul S., Charoenyingwattana A., Komindr S., Thongnak C., Mushiroda T., Nakamura Y., Chantratita W., Sungkanuparph S. Clin. Infect. Dis 2010, 50, 597–604. doi: 10.1086/650003.
- Lai C.L., Leung N., Teo E. K., Tong M., Wong F., Hann H. W., Han S., Poynard T., Myers M., Chao G., Lloyd D., Brown N. A. Gastroenterology. 2005, 129, 528–536. doi: 10.1016/j.gastro.2005.05.053.
- Wilhelmus K.R. Cochrane Database Syst Rev. 2015, 1, CD002898. doi: 10.1002/14651858.CD002898.pub5
- Ko W.C., Rolain J. M., Lee N. Y., Chen P. L., Huang C. T., Lee P. I., Hsueh P. R. Int. J. Antimicrob. Agents. 2020, 55, 105933. doi: 10.1016/j.ijantimicag.2020.105933.
- Hassan A.E.A., Abou-Elkhair R.A.I., Parker W. B., Allan P. W., Secrist III J. A. Eur. J. Med. Chem. 2016, 108, 616–622. doi: 10.1016/j.ejmech.2015.12.029.
补充文件
